Dr. Shim is a clinical psychiatrist and neuroscientist. He is currently practicing psychiatry at the Atlanta VA Medical Center and teaching and conducting research at the VA medical center and Emory.
Dr. Shim received a M.D. degree in the Chung-Ang University Medical College. He obtained a Ph.D. degree in psychopharmacology from Southern Illinois University, Department of Pharmacology. He completed residency and psychopharmacology fellowship at Yale University, Department of Psychiatry. He is currently an Associate Professor of Psychiatry and Behavioral Neuroscience at Emory University.
Dr. Shim studied the dysfunction of dopamine system related to schizophrenia in the laboratory of Benjamin S. Bunney, M.D. as a psychopharmacology fellow at Yale. He also studied synaptic plasticity in the hippocampus in the laboratory of Timothy Tyler Ph.D. at Department of Neurobiology, Northeast Ohio Medical University. Since then, his research has been centered on neuroplasticity for major mental illness. His recent research interest has been understanding the mechanistic relationship between traumatic brain injury and subsequent Alzheimer’s disease. His current research focuses on glycogen synthase kinase-3 (GSK-3) inhibitors including lithium as a novel therapeutic target for traumatic brain injury and Alzheimer’s disease.
neuroplasticity, glycogen synthase kinase 3 (GSK-3), traumatic brain injury, Alzheimer’s disease, schizophrenia
Shim S.S., Stuzmann G.E.: Inhibition of glycogen synthase kinase-3: an emerging target in the treatment of traumatic brain injury. J Neurotrauma 2016;1;33:2065-2076.
Shim S.S., Shuman M., Duncan E.: cGMP: An emerging role in the treatment of schizophrenia: A review. Schizophr Res 2016;170: 226–231
Shim S.S. Nadeem R.: Are NMDA receptor antagonists beneficial in the treatment of schizophrenia? J Psychiatr Res 2014;51:19-20.
Shim S.S., Hammonds M.D.: Four weeks lithium treatment alters neuronal dendrites in the rat hippocampus. Int J neuropsychopharmacol 2013;16:1373-82.
Shim S. S., Hammonds M.D., Tatsuoka C., Feng I-J.: Effects of 4 weeks lithium and olanzapine treatment on synaptic plasticity in hippocampal CA1 area. Neurosci Lett 2012;524:5-9.
Hammonds M.D., Shim, S.S.: Effects of 4 weeks lithium and olanzapine treatment on levels of BDNF, Bcl-2 and phosphorylated CREB in the hippocampus. Basic Clin Pharmacol Toxicol 2009;105:113–119.
Shim S. S.: Treatment-resistant schizophrenia: strategies for recognizing schizophrenia and treating to remission. Psychiatric Times 2009;27(8):16-18.
Shim S.S.: Lower Serum levels of lithium may produce efficacy without adverse effects (letter). Am J Geriat Psychiat 2009;17:625.
Gao K., Kemp D.E., Ganocy S., Shim S.S., Findling R.: Calabrese J.R.: Differential interactions between comorbid anxiety and substance use disorder in rapid cycling bipolar I or II disorder. J Affect Disord. 2008;110:167-173.
Shim S.S., Hammonds M.D., Kee B.S.: Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2007;258:16-27.
Nocjar C., Hammonds M.D., Shim S.S.: Chronic lithium treatment magnifiies learning in rats. Neuroscience 2007;150:774-788
Hammonds M.D., Shim S.S., Pingfu F., Calabrese J.R.: Effects of subchronic lithium treatment on levels of BDNF, Bcl-2 and phospho-CREB in the rat hippocampus. Basic Clin Pharmacol Toxicol 2007;100:356-359.
Shim S.S., Hammonds M., Ganocy S.J., Calabrese J.R.: Effects of lithium exposure on synaptic plasticity in the dentate gyrus of the hippocampus. Prog Neuropsychopharmacol Biol Psychiat 2007;31:343-347.